
"Promising Daily Treatment Slows Progression of Fatal Neurological Disease"
A new study has shown promise in treating the fatal neurodegenerative disease ALS, by targeting and stabilizing the SOD1 enzyme, which is involved in many cases of the disease. The "molecular stabilizer" S-XL6 successfully restored the protein's function and stopped its toxic effects in mice, rats, and dogs. The researchers are hoping to move the molecule to clinical trials in humans, with the potential to become a co-treatment for Biogen's Qalsody.
